What is the selection and review process?
A.Following the submission of a proposal, TPI will evaluate all non-confidential information, involving either Pfizer internal or external experts as appropriate. If necessary, one or more meetings with the Company could be held. If TPI decides to proceed with further due diligence, a one-way confidentiality and disclosure agreement (CDA) will be signed. This will allow a more in depth review of the company proposal and intellectual property. After signing the CDA, no further information is shared with Pfizer scientists. Finally, the proposals selected for investment have to be approved by the TPI Board. Q.
